迈瑞医疗回复：您好，谢谢关注。经过过去几年的历练，公司对集采等各项政策的理解和适应能力都在 加强，对政策解读的时效性、政策配合的积极主动性显著提升，这都为公司政策贯彻的执行力提供了充 分保障。 对迈瑞来说，集采使公司的国内市场占有率大幅提升，而毛利率却没有太大变化，这其中的 关键是公司掌握了核心技术。展望未来，国内市场需要长期拥抱医保政策变化，公司也将继续积极主动 地去顺应这些政策带来的变化，抓住机遇，力争更好的发展。谢谢。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，迈瑞医疗(300760)10月14日在投资者关系平台上答复投资者关心的问题。 投资者提问：请问公司2025年受集采低价竞争的影响如何？ 谢谢 ...

Core Viewpoint - The article discusses the performance of the Chuangye 50 ETF (159682) and its major holdings, highlighting a positive market trend with notable gains in several key stocks [1]. Group 1: ETF Performance - The Chuangye 50 ETF (159682) opened with a gain of 1.07%, priced at 1.415 yuan [1]. - Since its inception on December 23, 2022, the fund has achieved a return of 40.16% [1]. - The fund's performance over the past month has been a return of 2.06% [1]. Group 2: Major Holdings - Key stocks in the Chuangye 50 ETF include: - Ningde Times, which opened with a gain of 1.74% [1]. - Dongfang Wealth, up by 0.31% [1]. - Huichuan Technology, increasing by 1.21% [1]. - Zhongji Xuchuang, rising by 2.12% [1]. - Mindray Medical, gaining 1.06% [1]. - Xinyi Sheng, up by 2.04% [1]. - Sunshine Power, increasing by 2.56% [1]. - Shenghong Technology, rising by 2.95% [1]. - Yiwei Lithium Energy, up by 0.10% [1]. - Tonghuashun, gaining 0.56% [1]. Group 3: Management Information - The Chuangye 50 ETF is managed by Invesco Great Wall Fund Management Co., Ltd. [1]. - The fund managers are Wang Yang and Zhang Xiaonan [1].

风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 10月14日，双创龙头ETF（588330）开盘涨0.78%，报0.904元。双创龙头ETF（588330）重仓股方面， 宁德时代开盘涨1.74%，中芯国际涨0.36%，迈瑞医疗涨1.06%，海光信息涨1.97%，中际旭创涨2.12%， 寒武纪涨0.78%，新易盛涨2.04%，汇川技术涨1.21%，阳光电源涨2.56%，澜起科技涨2.15%。 双创龙头ETF（588330）业绩比较基准为中证科创创业50指数收益率，管理人为华宝基金管理有限公 司，基金经理为胡洁，成立（2021-06-29）以来回报为-10.24%，近一个月回报为3.88%。 来源：新浪基金∞工作室 ...

Summary of Conference Call Notes Industry Overview - **Industry**: China Healthcare - **Quarter**: 3Q25 Key Companies and Revenue Growth Companies with Higher Revenue Growth 1. **United Imaging** - Expected revenue growth: **44% YoY** in 3Q25 - Growth driven by improved hospital bidding data in China [1][6] 2. **Lepu** - Expected revenue growth: **38% YoY** in 3Q25 - Growth factors: - Low base effect from 3Q24 due to "Four Same" policy impacting pharmaceutical business - Incremental revenue from consumer healthcare segment, particularly medical aesthetics [1][6] 3. **Gan & Lee Pharmaceuticals** - Expected revenue growth: **23% YoY** in 3Q25 - Benefits from insulin VBP renewal and progress in overseas expansion [1][6] Companies Under Pressure 1. **Zhifei** - Currently in the trough of its revenue cycle - Revenue expected to decline by **30% YoY** in 3Q25 - Increased competition following Wantai's launch of a 9-valent HPV vaccine - Offering discounts to accelerate inventory destocking [2][6] 2. **ICL Companies (Kingmed and Dian Diagnostics)** - Expected to post negative revenue growth in 3Q25 - Industry pricing pressure has stabilized, indicating potential for positive growth in 4Q25 [2][6] Financial Estimates and Changes - **Tonghua Dongbao**: Revised annual earnings estimates upward due to market share gains post-insulin VBP renewal [7] - **Kelun**: Revised net profit estimates downward due to ongoing price war in the API industry, while revenue estimates remain unchanged [7][10] Detailed Financial Estimates Exhibit 1: Revenue and Earnings Growth Preview - **United Imaging**: Revenue from **1,621 million** to **2,327 million** (44% YoY) - **Lepu**: Revenue from **1,402 million** to **1,937 million** (38% YoY) - **Gan & Lee**: Revenue from **930 million** to **1,140 million** (23% YoY) - **Zhifei**: Revenue from **4,528 million** to **3,177 million** (-30% YoY) [6] Exhibit 2: Updated Estimates for Tonghua Dongbao (2025E to 2027E) - **Revenue**: Increased from **2,612 million** to **2,689 million** (3.0% change) - **Net Profit**: Increased from **401 million** to **408 million** (1.5% change) [8] Exhibit 3: Updated Estimates for Kelun (2025E to 2027E) - **Revenue**: Remains at **19,029 million** (0.0% change) - **Net Profit**: Decreased from **2,791 million** to **2,686 million** (-3.8% change) [10] Risks and Methodology - **Mindray**: Target price of **Rmb314** with risks including VBP impacts and market penetration challenges [12][13] - **SNIBE**: Target price of **Rmb73** with risks from competition and policy changes [14] - **Hualan**: Target price of **Rmb19** with risks from regulatory changes and competition [15] - **Tonghua Dongbao**: Neutral rating with target price of **Rmb9**, risks from product sales ramp-up and competition [17] - **Kelun**: Neutral rating with target price of **Rmb38**, risks from API price declines [18] Conclusion - The China healthcare sector is experiencing varied growth dynamics, with certain companies like United Imaging and Lepu showing strong revenue growth, while others like Zhifei face significant challenges. The financial estimates reflect these trends, with adjustments made based on market conditions and competitive pressures.

Market Overview - The medical device sector experienced a decline of 1.35% on October 13, with Nanwei Medical leading the drop [1] - The Shanghai Composite Index closed at 3889.5, down 0.19%, while the Shenzhen Component Index closed at 13231.47, down 0.93% [1] Top Performers - Zhendemedical (603301) saw a closing price of 60.44, with a rise of 7.05% and a trading volume of 166,300 shares [1] - Wuzhou Medical (301234) closed at 46.22, up 6.13%, with a trading volume of 32,400 shares [1] - BGI Genomics (688114) closed at 72.35, increasing by 4.99% with a trading volume of 89,300 shares [1] Underperformers - Nanwei Medical (688029) closed at 91.15, down 6.78% with a trading volume of 42,800 shares [2] - Kangzhong Medical (688607) closed at 26.57, down 4.60%, with a trading volume of 25,700 shares [2] - Mindray Medical (300760) closed at 235.20, down 2.81%, with a trading volume of 108,600 shares [2] Capital Flow - The medical device sector saw a net outflow of 412 million yuan from institutional investors, while retail investors contributed a net inflow of 325 million yuan [2][3] - The top net inflow from retail investors was observed in Mindray Medical, with 2.63 million yuan, while Zhendemedical experienced a net outflow of 55.19 million yuan from retail investors [3]

Core Insights - The article highlights the trend of net inflows of main funds into specific stocks, with a total of 80 stocks experiencing net inflows for five consecutive days or more as of October 13 [1] Group 1: Key Stocks with Continuous Net Inflows - Han's Laser (寒武纪-U) leads with 33 consecutive days of net inflows, totaling 4.475 billion yuan, with a price increase of 35.13% [1] - Agricultural Bank (农业银行) follows with 7 days of net inflows amounting to 1.625 billion yuan and a price increase of 5.18% [1] - ZhenDe Medical (振德医疗) has 11 days of net inflows totaling 468 million yuan, with a significant price increase of 49.98% [1] Group 2: Notable Stocks by Net Inflow Proportions - *ST Dongyi (维权) has the highest proportion of net inflows relative to trading volume, with a recent price increase of 27.66% [1] - Other notable stocks include Huaneng Power (国电南自) with a net inflow of 384 million yuan and a price increase of 23.81% over 6 days [1] - The stock of Oriental Cable (东方电缆) recorded a net inflow of 366 million yuan with a price increase of 16.44% over 8 days [1]

资金流向方面，生物经济（970038）指数成份股当日主力资金净流出合计7.22亿元，游资资金净流入合 计1.88亿元，散户资金净流入合计5.34亿元。成份股资金流向详情见下表： 证券之星消息，10月13日，生物经济（970038）指数报收于2325.47点，跌1.85%，成交314.96亿元，换 手率2.07%。当日该指数成份股中，上涨的有6家，华测检测以2.51%的涨幅领涨，下跌的有44家，博腾 股份以6.27%的跌幅领跌。 生物经济（970038）指数十大成份股详情如下： | 证券代码 | 股票简称 | 权重 | 最新价 | 涨跌幅 | 总市值(亿元) | 所属行业 | | --- | --- | --- | --- | --- | --- | --- | | sz300760 | 迈瑞医疗 | 13.81% | 235.20 | -2.81% | 2851.66 | 医药生物 | | sz000661 | 长春高新 | 5.41% | 132.06 | -3.11% | 538.72 | 医药生物 | | sz300759 | 康龙化成 | 4.66% | 31.76 | -3.99% | 564.75 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [1] Core Viewpoints - The impact of the tariff war on the pharmaceutical sector is limited, with a positive outlook on innovation and domestic substitution [1][16] - The ranking of favored sub-industries is: innovative drugs > research services > CXO > traditional Chinese medicine > medical devices > pharmacies [2][10] - Specific stock recommendations include Zhaoli Pharmaceutical, Fangsheng Pharmaceutical, and Dong'e Ejiao from the traditional Chinese medicine sector, and Yuyue Medical and United Imaging Healthcare from the medical device sector [2][11] Summary by Sections Industry Trends - The A-share pharmaceutical index has seen a year-to-date increase of 21.87%, while the Hang Seng Biotechnology Index has increased by 94.11% [5][10] - Recent stock performance highlights include Zhend Medical (+21.00%) and Wanbangde (+12.01%) in A-shares, while Hong Kong stocks like Kaisa Health (+48.84%) have also performed well [5][10] Tariff Policy Analysis - The U.S. tariff policy on pharmaceuticals is expected to have minimal impact on China's pharmaceutical industry, as most exports consist of raw materials [16][22] - The tariff primarily affects brand-name and patented drugs, while generic drugs and raw materials are largely exempt [16][19] R&D Progress and Company Dynamics - Significant advancements in innovative drug development include the initiation of Phase III clinical trials for the first selective CDK2 inhibitor and breakthroughs in ADC treatments for triple-negative breast cancer [5][10] - The report emphasizes the importance of research quality and efficiency in CRO services, which remain unaffected by tariff policies [16][22] Market Performance Review - The pharmaceutical index's P/E ratio stands at 39.05, slightly above historical averages, indicating a robust market outlook despite recent fluctuations [5][10] - The report notes that the recent stock price declines in the innovative drug sector are primarily driven by market sentiment rather than fundamental changes [22]

行 业 及 产 业 医药生物 2025 年 10 月 12 日 本 周 申 万 医 药 生 物 指 数 下 跌 行 业 研 究 / 行 业 点 评 本期投资提示： ⚫ 市场表现：本周申万医药生物指数下跌 1.2%，同期上证指数上涨 0.4%，万得全 A（除 金融石油石化）下跌 0.5%。本周医药生物指数在 31 个申万一级子行业中表现排名第 25 。 各 三 级 板 块 涨 跌 幅 为 ： 原 料 药 （ -0.7% ） 、 化 学 制 剂 （ -2.5% ） 、 中 药 （+1.5%）、血液制品（+1.4%）、疫苗（+0.7%）、其他生物制品（-1.7%）、医疗 设备（-0.2%）、医疗耗材（+0.2%）、体外诊断（-0.6%）、医药流通（+0.8%）、 线下药店（+0.3%）、医疗研发外包（-5.3%）、医院（+1.8%）。当前医药板块整体 估值 30.9 倍，在 31 个申万一级行业(2021)中排名第 10。 本研究报告仅通过邮件提供给 中庚基金 使用。1 《本周医药上涨 3.1%，医保局发布按病种 付费管理暂行办法和医保"双目录"初审 名单，司美在美获批治疗 MASH ——医药 行业周报（2025/ ...

Investment Rating - The report indicates a positive investment outlook for the innovative pharmaceutical sector, suggesting a focus on companies with sustained high growth in performance [3][4][11]. Core Insights - The innovative pharmaceutical industry is expected to continue its high revenue growth trend, with specific attention on companies in the medical devices, CXO, and upstream sectors [3][4]. - The report highlights the performance forecasts for 22 pharmaceutical companies, with several expected to achieve significant profit growth in Q3 2025 [3][4]. - The report emphasizes the importance of monitoring companies that consistently maintain high growth rates, such as 恒瑞医药 (Hengrui Medicine), 迈瑞医疗 (Mindray), and others [3][4][11]. Performance Forecasts - As of October 11, 2025, two pharmaceutical companies have released their Q3 2025 performance forecasts, with 重药控股 (Zhongyao Holdings) expecting a profit growth rate between 39.89% and 117.47%, and ST 诺泰 (ST Nuotai) expecting a growth rate between 5.62% and 13.74% [4]. - The report predicts that five companies will achieve profit growth rates of 40% or more, including 以岭药业 (Yiling Pharmaceutical) and 福瑞股份 (Furui Co.) [3][4]. - Revenue forecasts for 33 pharmaceutical companies indicate that seven companies are expected to achieve revenue growth rates of 40% or more, including 三生国健 (3SBio) and 艾迪药业 (Eddie Pharmaceuticals) [3][4]. Company-Specific Insights - The report provides detailed profit and revenue forecasts for various companies, indicating significant expected growth for companies like 以岭药业 (Yiling Pharmaceutical) with a projected profit increase of 1150% year-on-year [6][9]. - Specific revenue growth rates are forecasted for companies such as 恒瑞医药 (Hengrui Medicine), which is expected to achieve a revenue increase of 12% to 17% [10][11]. - The report includes a valuation table for key companies, indicating projected earnings per share (EPS) and price-to-earnings (PE) ratios for the coming years [11].